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Summal~ 
Lethally irradiated mice transplanted with bone marrow cells infected with a novel recombinant 
retrovirus (murine stem cell virus-interleukin 6 [MSCV-II.,6]) bearing a mouse Ib6 gene developed 
a fatal myeloproliferative disease within 4 wk of engraftment. The hematologic manifestations 
of the syndrome included elevated peripheral leukocyte counts (up to 430  x  103 cells/mm 3) with 
a  predominance  of  neutrophilic  granulocytes,  microcytic  anemia,  and  thrombocytosis  or 
thrombocytopenia. The mice showed extensive neutrophil infiltration  of the lungs, liver, and 
occasionally lymph nodes, plus splenomegaly resulting from enhanced splenic myelopoiesis (30-60- 
fold increase in progenitor numbers).  Despite  the chronic stimulation of neutrophil excess by 
IL-6, bone marrow from affected mice was capable of repopulating the hematopoietic tissues 
(bone marrow and spleen) of lethally irradiated hosts during repeated serial transplantation.  In 
the longest documented case, the progeny of a single MSCV-IL-6-marked cell transferred  the 
myeloproliferative disease to two secondary, four tertiary,  and two quaternary recipients  (the 
clone endured for a total of 72 wk). These results, demonstrating considerable proliferative  longevity 
of the Ib6-producing cells, support  an in vivo role of IL,6 in the maintenance of hematopoietic 
precursors. Dysregulated Ib6 production also had significant systemic effects. The mice displayed 
increased mesangial cell proliferation  in the kidney, frequent liver abnormalities,  and marked 
alterations  in plasma protein levels. Unlike previous  studies where constitutive expression of 
exogenous Ib6 genes resulted in lymphoprollferative  disorders characterized  by massive  plasmacytosis, 
minimal plasma cell expansion occurred in the MSCV-Ib6 mice during the observation period. 
Potential explanations for the differences  in disease phenotypes observed in the present and previous 
studies are different cell types expressing the exogenous II.-6 genes, higher sustained circulating 
levels of IL-6 achieved using the MSCV-IL-6 retroviral  delivery system, and/or the premature 
death (3-15 wk after transplantation)  of the MSCV-IL-6 mice before the onset of plasmacytosis. 
This animal model should prove useful for further investigation of the function of IL-6 in normal 
and abnormal hematopoiesis  and in inflammatory responses. 
M 
ature blood cells have short life spans. Consequently, 
they are replenished continuously throughout life from 
a small population of undifferentiated precursors (stem cells) 
(1). Besides their differentiative potential, stem cells have ex- 
tensive self-maintaining (self-renewal)  capacity. It is this unique 
property of self-renewal that distinguishes  stem cells from 
committed hematopoietic progenitor cells. Although a large 
body of data has been accumulated identifying the growth 
factors (cytokines) that act on progenitor cells (2), little is 
known about the factors that govern stem cell numbers or 
the regulatory mechanisms controlling the production of pro- 
genitor cells by stem cells in vivo. 
In adults, hematopoiesis occurs mainly in the bone marrow 
where specialized stromal cells are believed to maintain steady- 
state levels of hematopoietic stem cells through the concerted 
actions of multiple membrane-bound and short-range factors 
(3). The recently described c-kit ligand (KL; also referred to 
as stem cell factor, or mast cell growth factor), whose defec- 
tive expression in mice of the Steel genotype results in severe 
anemia and stem cell deficiency, is clearly an important con- 
tributor to basal hematopoiesis  (4).  Indirect  evidence sug- 
gests that IL-6, a pleiotropic cytokine produced by a variety 
of cell types, including bone marrow stromal cells (5), may 
also be important for normal hematopoietic development (6, 
7). Originally identified because of its immune and inflam- 
matory properties  (8),  subsequent  studies have revealed an 
impressive range of activities of Ib6 on early hematopoietic 
cells. Most relevant in this regard has been the demonstra- 
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Volume  176  October 1992  1149-1163 tion  that  IL-6 can act in concert with  IL-3 to increase the 
in  vitro  number  of stem  ceUs providing  long-term,  mul- 
tilineage engraftment of lethally irradiated mice (9, 10). The 
combination of II.-6 with IL-3 or KL also increases  exoge- 
nous numbers  of stem cells with  short-term  repopulating 
potential,  as well as progenitors capable of forming splenic 
myeloerythroid colonies (CFU-spleen [S] 1) (9-12).  Numer- 
ous other studies have documented the ability oflb6 to stimu- 
late the in vitro production of multipotential and restricted 
progenitors of the myeloid, erythroid,  and megakaryocytic 
lineages and their progeny (5, 13-19). In the mouse, Ib6 by 
itself directly supports the proliferation  and differentiation 
of some granulocyte/macrophage progenitor cells (14, 15, 20). 
Compared with in vitro studies,  there have been limited 
reports of in vivo effects of IL-6 on the hematopoietic stem/pro- 
genitor cell compartment.  Administration  of I1r  to mice 
increased recovery of bone marrow and spleen CFU-S numbers 
and myeloerythroid progenitor numbers after chemotherapy- 
or radiation-induced hematopoietic injury (21,  22). Similar 
treatment of normal mice with II~6 enhanced production of 
CFU-S and granulocyte/macrophage progenitors transiently 
in the spleen (22, 23), with the number of these cell types 
in bone marrow being either slightly elevated or remaining 
relatively unchanged in different treatment regimens (22, 24, 
25). Modest increases  in the circulating numbers of neutro- 
phils and platelets and mild erythropoietic effects have also 
been observed after in vivo administration  of IIr  (24-26). 
An alternative approach to examine the effects of exoge- 
nous gene products on hematopoietic processes is to introduce 
the corresponding genes directly into stem cells with retrovirus 
vectors (27). The recombinant retroviruses can then be used 
as tags to follow the fates of stem cell clones during  serial 
bone marrow transplantation (28-34). When cytokine genes 
have been transferred into hematopoietic cells in this manner, 
their  dysreguhted  expression routindy  elicits  hyperplastic 
hematologic disorders that are frequently fatal (35-39). There 
has been limited documentation,  however, of the ability to 
transfer the disorders to secondary recipients (37-39),  thus 
precluding systematic evaluation of the consequences of long- 
term cytokine exposure on the stem cell pool. A basic ques- 
tion that remains unanswered for any factor is whether chronic 
overproduction of mature hematopoietic cells depletes stem 
cells  or diminishes  their  self-renewal capacity. 
Because sustained  high-level  expression of nonselectable 
genes after serial transplantation  of retrovirus-infected stem 
cells has been infrequent  (9, 40-42),  we used an improved 
infection protocol (9) and a new high-titer retrovirus vector 
for the current studies in an attempt to reduce the possibility 
of deficiencies in the gene transfer methodology (inefficient 
introduction of transcriptionally active genes into stem cells 
or extinction of gene expression with time [29,  38]) com- 
1 Abbre~lions used in thispaper: CFC, colony-forming cells; CFU-S, colony 
forming unit-spleen;  MCV, mean corpuscuhr volume; MESV, routine 
embryonic stem cell virus; MoMLV, Moloney murine leukemia virus; MPV, 
mean platelet volume; MSCV, murine stem cell virus;  neo,  neomycin 
phosphotransferase; pgk-1, phosphoglycerate kinase-1. 
plicating the interpretation of the data. A previously described 
retrovirus  vector from  this  laboratory  (L6PNL) bearing  a 
mouse IL-6 gene and the bacterial neomycin phosphotrans- 
ferase (neo) gene (43) was modified by incorporating  those 
sequences from the murine embryonic stem cell virus (MESV) 
that have recently been shown to facilitate the expression of 
exogenous genes in embryonic stem cells (44). The resulting 
IL-6 murine stem cell virus (MSCV-IL-6)  was utilized herein 
to evaluate the repopulating potential of II~6-producing, bone 
marrow precursors. 
Materials  and Methods 
MSCVIL-6 Retrovirus Vector  and Cell Lines.  To simplify plasmid 
constructions with MSCV vectors, the MESV retrovirus backbone 
of P5Gneo (a gift of M. Grez, Heinrich-Pette-Institut,  Hamburg, 
Germany) (44) was subcloned into a pUC8-based plasmid (45). The 
majority of the LTR sequences in L6PNL (43) and all internal se- 
quences from an NheI site in the 5' LTR to a KpnI site in the 
3' LTR were replaced with the corresponding P5Gneo sequences 
contained on a 1.9-kb NheI-XhoI fragment  and a 3.2-kb XhoI- 
Kpn[ fragment. To construct MSCV-IL-6 (Fig. 1), the gag-neo se- 
quences of the resulting plasmid PUC5Gneo were deleted from 
an SpeI site (position 292) to a HindIII site present in the envelope 
region, and a 3.0-kb SpeI-HindIII fragment of L6PNL-containing 
gag-IL-6-pgk-neo sequences was inserted.  The net result of these 
manipulations was the substitution of the viral transcriptional con- 
trolling sequences and 5' untranslated region in L6PNL shown to 
be involved in the restriction of viral gene expression in embryonic 
stem ceils with the corresponding elements from MESV that are 
permissive for gene expression in these cells. 
A general MSCV vector was derived from MSCV-Ib6 by ex- 
cising the IL-6 sequences with EcoRI. The salient features of the 
MSCV vector design include variant LTRs (from PCMV, a mu- 
tant of the myeloproliferative sarcoma virus expressed in PCC4 em- 
hryonal carcinoma cells) (46) and a modified 5' untranslated region 
(from dl-587rev, an endogenous  mouse retrovirus  containing  a 
tRNA  G~ primer binding site instead of tRNA ~) (47) for e~cient 
LTR-directed expression in embryonic stem cells, a functional splice 
donor, and an extended packaging region (gt*) for high viral titer 
containing mutations that abolish the synthesis of any gag-related 
polypeptides and eliminate the need for splicing to express inserted 
N  E  E  B  N 
t___. 
Figure 1.  Schematic  representation of MSCV-I1,6 retr~4rus vector. The 
LTKs of M$CV-IL-6  (denoted PCMV) and the 5' untranslated region (in- 
dicated by tRNA  GIn) permit eflficient  LTR-directed expression of exoge- 
nous genes in embryonic stem cells. Arrows indicate the LTK and pgk-1 
(pgk) promoters utilized for expression of the mouse I1,6 (raiL-6) gene 
and the bacterial neo gene, respectively. Also indicated are the NheI (N) 
and BamHl (B) restriction  sites, which permit assessment of vector se- 
quence transmission and quantitation of proviral integration sites, respec- 
tively. Not shown are the splice donor and acceptor sites within the ex- 
tended  packaging  region (r  that  result  in a  spliced II--6 mRNA 
normally present as a minor species in MSCV-Ib6-infected cells. As de- 
scribed in Materials and Methods,  a prototype  MSCV retrovirus vector 
was generated by excision of the II-6 gene with EcoRI  (E). 
1150  lnterleukin 6-induced Myeloproliferative Disease genes (48). The neo gene in MSCV contains a synthetic initiation 
sequence favorable for translation in mammalian ceils and has been 
placed  under  the  transcriptional  control  of an  internal  phos- 
phoglycerate kinase (pgk-1) promoter for constitutive expression 
in a wide range of cell types (49). In the final version of MSCV, 
all envelope sequences have been deleted by incorporation of a syn- 
thetic oligonucleotide fragment from LNCX (48), and unique re- 
striction enzyme sites  (EcoRI,  HpaI,  XhoI,  BglII)  have been 
provided for insertion of genes 5' of the pgk-1 promoter (oligonu- 
cleotides synthesized by the University of Ottawa Biotechnology 
Research Institute [3808; Applied Biosystems, Inc., Foster City, 
CA]). Subeloning was carried out using standard recombinant DNA 
procedures  (50). All MSCV vectors and the exact details of their 
construction are available upon request. 
Recombinant virus was produced from clonal isolates of GP+E- 
86 ecotropic helper-free packaging cells (51), generated as described 
previously by infection of tunicamycin-treated cells with superua- 
tant from transient transfectants (43). The cellline used for all gene 
transfer experiments,  GP+ E-86/MSCV-IL-6 c2.12, produces struc- 
turally intact MSCV-Ib6 virus with a titer of 2  x  106 G418- 
resistant CPU/ml when assayed on NIH3T3 fibrobhsts. CeUs were 
maintained in DME with 4.5 g/liter glucose supplemented with 
10% FCS (HyClone Lab) in a humidified atmosphere containing 
5%  CO2 at 37~ 
Retrovirus Infection and Transplantation of Bone Marrow. Female 
BALB/c mice (Charles  River Breeding Laboratory) were used at 
6-8 wk of age as bone marrow donors and recipients. Bone marrow 
processing,  infection, and transplantation were carried out using 
a slightly modified version of  published procedures (9, 43, 52). Bone 
marrow was flushed from hind limbs of donors injected 4 d previ- 
ously with 150 mg/kg 5-fluorouracil  with ice-cold IMDM con- 
taining 50 ~tM 2-ME and 10% heat-inactivated FCS (Gibeo Labora- 
tories,  Grand  Island,  NY).  After erythrocyte lysis in  0.17 M 
ammonium chloride, nucleated cells were added to 100-mm petri 
dishes (Fisher Scientific) at a density of 5  x  105 cells/m1 in IMDM 
supplemented with 50 ~M 2-ME, 10% heat-inactivated FCS, 10% 
conditioned medium from X630-rlL-3 cells (a source of Ib3; a gift 
of F.  Melchers,  Basel, Switzerland) (53),  and 10%  conditioned 
medium from Sp2/mIL-6 ceils (a source of IL-6) (54). After 48 h, 
the bone marrow cells were collected and added to subconfluent 
monolayers of GP+E-86/MSCV-IL-6 c2.12 cells in 100-mm tissue 
culture dishes (Nunc Roskilde, Denmark) at a density of 5  x  10  s 
cells/ml in IMDM supplemented with 50 #M 2-ME, 10% heat- 
inactivated FCS,  10%  X630-rIL-3-conditioned  medium,  and  8 
/zg/ml polybrene. After a further 48 h, nonadherent bone marrow 
cells were harvested, centrifuged, and resuspended in fresh coculti- 
vation medium containing 0.75 mg/ml G418 (Gibco Laboratories, 
Grand Island,  NY). These cells were collected 24 h later and in- 
jected via the tail vein into recipients  that had received 7 Gy of 
irradiation (GammaceU 40; Atomic Energy of Canada). In some 
experiments,  the G418 selection was omitted. Each mouse received 
between 5  x  10  s and 2  x  106 cells. For serial transplantations, 
106 bone marrow cells from affected animals were injected intra- 
venously into lethally irradiated (7 Gy) recipients. Mice were housed 
one to three per sterilized microisolater cage on laminar flow racks. 
The colony was periodically tested for a panel of viruses by analysis 
of serum samples (Charles River Professional Services, W'dmington, 
MA). Animals repeatedly tested negative for sendai virus,  pneu- 
monia virus of mice, mouse hepatitis virus, minute virus of mice, 
mouse polio virus, and reovirus type 3. The animals were also found 
to be free of mycoplasma. 
Hematologic and Pathologic Analysis.  Blood was collected from 
the retroorbital sinus at weekly intervals after transplant and im- 
mediately  before death. Total leukocytes (WBC), total erythrocytes 
(RBC), hemoglobin, hematocrit, mean corpuscular volume (MCV), 
total platdets, and mean platdet volume (MPV) were determined 
on a cell counter (System 9000 Hematology Series; Serono-Baker 
Instruments) equipped with a veterinarian  software package (43). 
Granulocytic predominance of leukocytes suggested by the auto- 
mated differential leukocyte count was confirmed by performing 
a manual differential count of Wright-stained blood smears. Con- 
trols were mice transplanted with hematopoietic ceils infected with 
a derivative of MSCV carrying a PKC gene (55; our unpublished 
results)  as well as age-matched littermates. 
Mice were killed by cervical dislocation when moribund and 
necropsy examinations were performed immediately after death. 
Tissues were preserved in B5 fixative for 2 h, stored in 10% neutral- 
buffered formalin, then embedded in para~n, sectioned, and stained 
with hematoxylin and eosin before examination by light micros- 
copy (43, 56). Tissues examined included spleen, thymus, lungs, 
heart, liver, pancreas, kidneys, lymph nodes,  and sternum (bone 
marrow). 
In Vitro Progenitor Cell Assay.  The number of colony-forming 
ceils (CFC)was determined by plating nucleated bone marrow (at 
103 and 104 ceils/ml) and spleen ceils (at 10  ~, 104, 10  s cens/ml) in 
duplicate 1-ml cultures (35-mm Lux suspension plates; Miles) con- 
taining c~-MEM, 0.8% methylceilulose,  30% FCS, 1% BSA, 100 
/~M 2-ME,  3  U/ml  erythropoietin,  and  1%  PWM-stimulated 
spleen-conditioned  medium (Terry  Fox Laboratory,  Vancouver, 
Canada) as described (57). Where indicated, G418 was added to 
a final concentration of 1 mg/ml. Colonies (consisting of >50 cells) 
of erythroid ceils, granulocytes, macrophages, and mixtures of these 
were enumerated using an inverted microscope on day 7 and recorded 
together as CFC. 
Bioassays.  Ib6  activity in  culture  supernatants  and  plasma 
samples was detected by 139 microproliferation assay (58) essentially 
as described (43). The cells were propagated in IMDM supplemented 
with 50 #M 2-ME, 5% heat-inactivated FCS, and 2% conditioned 
medium from Sp2/mIb6 ceils (54). For the assay, B9 cells were 
harvested by centrifugation, washed twice in medium lacking Ib6, 
and then used at 104 cells/200 #1 well in the presence of twofold 
dilutinns of samples to be tested. Cells were labded with 0.2 ~Ci 
[3H]TdR (New England Nuclear, Boston, MA) at 64-72 h. The 
incorporated radioactivity was determined for triplicate  cultures 
by liquid sdntillation counting (Betaplate,  Wallac) after transfer 
of cellular debris  to glass fiber filters with a cell harvester  (Ska- 
tron). The standard deviation of the mean of triplicate cultures was 
always <15%. Each assay was standardized with human rib6 (R&D 
Systems), and values (ng/ml human Ib6 equivalents) were calcu- 
lated by probit analysis. When included, a rat mAb against mouse 
Ib6 (59) (a gift of L. Sachs, Weizmann Institute, Rehovot, Israel) 
completely neutralized the B9 proliferative activity in the plasma 
samples. Microwell cuhures of OTT1 (responsive to GM-CSF, Ib3, 
and IL,5), FDC-P1  (responsive to GM-CSF and IL-3), and 32D 
(responsive to Ib3) calls were similarly used to assay GM-CSF and 
IL-3 as described  (60, 61). 
Cellulose Acetate Electropkoresis of  Plasma Samples.  Electrophoretic 
separations of plasma proteins were performed in barbital-sodium 
barbital buffer according to the manufacturer's instructions (Sepratek 
System, Gelman Sciences). Briefy, electrophoresis was for 20 min 
at 225 V on cellulose acetate strips soaked in the buffer for 10 rnin 
before sample application.  After electrophoresis,  the strips were 
stained and fixed for 10 min in 0.5% Ponceau S/7.5% TCA, de- 
stained for 15 min in 5% acetic acid, and cleared in 40.0% aqueous 
N-methyl  pyrrolidone  before  scanning  by  laser  densitometry 
(Ultrascan  XL; Pharmacia  LKB, Hscataway,  NJ). 
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was digested with BamHI  (which cleaves uniquely within the 
vector), and proviraljunction fragments were identified  by Southern 
blotting using a 1.0-kb BgllI-SmaI fragment of the neo gene as 
probe (62). Structural integrity of MSCV-IL-6 proviruses was as- 
sessed by Southern blot analysis of NheI-digested DNA. Total cel- 
lular RNA (10/~g) was analyzed by Northern blotting for viral 
RNA transcripts using a 0.6-kb EcoRI-BgllI fragment of the mouse 
I1:6 cDNA as probe (63). After exposure to film, the blots were 
stripped and rehybridized with the neo probe to assess the relative 
levels of LTR- and pgk-l-initiated transcripts. The blots were sub- 
jected to a final hybridization with a 1.2-kb PstI fragment of the 
rat glyceraldehyde-3-phosphate  dehydrogenase  gene (64). Southern 
and Northern blot analyses  were carried out according to standard 
procedures (50). 
Results 
Rationale  for  Construction  of the  MSCV-IL6  Retrovirus 
/~ctor.  We previously reported the engraftment of lethally 
irradiated BALB/c mice with bone marrow cells infected with 
the L6PNL retrovirus carrying a mouse I1:6 gene transcribed 
from the Moloney murine leukemia virus (MoMLV) LTR 
(43).  The presence of the bacterial neo gene in the L6PNL 
virus permitted the isolation of G418-resistant populations 
of macrophages, mast cells, and T cells from hematopoietic 
tissues of recipients for lineage analyses and RNA expression 
studies up to 10 mo after transplantation. The results demon- 
strated  transfer  of  functional  L6PNL  retroviruses  into 
repopulating stem cells capable of long-term multilineage 
reconstitution. In all cases, however, the levels of viral II.-6 
mKNA were found to be considerably lower than the corre- 
sponding levels of neo mRNA, which originated from an 
internal pgk-1 promoter in the L6PNL virus. Low-level ex- 
pression of the introduced II.-6 gene evoked minor hemato- 
logic changes in the animals: a mild myeloproliferative effect 
with moderate increases in circulating neutrophil numbers. 
These findings contrasted with the considerable effects reported 
by Brandt  et  al.  (39)  in  unirradiated,  stem cell-defective 
W/W v  mice  receiving  bone  marrow  infected  with  a 
different Ib6 retrovirus. Most of the mice in the latter study 
developed a syndrome characterized by massive plasma cell 
hyperplasia. A similar lymphoproliferative disease had previ- 
ously been observed in transgenic mice expressing a human 
I1:6 gene under the control of an Ig heavy chain enhancer (65). 
Besides  differences in  infection regimens, differences in 
retrovirus constructs could account for the discordant results 
obtained in these studies. Since the LTRs and 5' untranslated 
region of the MESV retrovirus vector were recently found 
to alleviate the restriction block experienced by MoMLV-based 
vectors in embryonic stem cells (44),  we felt it desirable to 
incorporate these MESV components into the L6PNL vector 
before undertaking further experiments aimed at examining 
the effects of chronic Ib6 overproduction on early hemato- 
poietic cells. The modified I1:6 retrovirus vector, designated 
MSCV-I1:6  to reflect its derivation from MESV, is illustrated 
in Fig.  1. 
The effective titer of helper-free recombinant MSCV-IL-6 
produced by a clonal isolate of GP+ E-86 packaging cells was 
2  x  105 G418-resistant  CFU/ml when assayed on the ex- 
tremely nonpermissive P19 embryonal carcinoma cell line (66). 
This frequency of functional neo gene transfer into P19 cells 
represents an '~40-fold improvement over that previously ob- 
tained with other retrovirus constructs (49) and is only 10- 
fold less than the titer obtained on fibroblasts.  More impor- 
tant, unlike the situation experienced with L6PNL proviruses 
in P19 cells, where virtually no LTR-initiated Ib6 transcripts 
could be detected, viral Ib6 RNA  species were present in 
MSCV-II:6-infected P19 cells at levels comparable to the neo 
transcripts originating from the pgk-1 promoter (data not 
shown). 
Fatal Hematologic Disease Develops in Mice Receiving MSCV 
IL,6-infected Hematopoietic Cells.  Lethally irradiated BALB/c 
mice received intravenous inoculations of MSCV-Ib6-infected 
bone  marrow  cells  (~106  cells).  Bone  marrow  infections 
were carried out according to protocols described previously 
except  that  exposure to  virus-producing  monolayers was 
preceded by a 48-h incubation in medium supplemented with 
I1:3 and IL-6. Inclusion of the prestimulation step has been 
shown to improve the efficiency of gene transfer into long- 
term repopulating cells (9). Under these experimental con- 
ditions, each inocnlum contained 1-4  x  105 progenitor cells 
as determined by 7-d methylcellulose CFC assay (,,o50%  of 
which were G418 resistant), a 10-fold increase over previous 
numbers (43).  Beginning 3  wk after transplantation,  the 
MSCV-IL-6 mice developed leukocytosis (peripheral leuko- 
cyte  count  routinely  in  the  range  of  100-300  x  103 
cells/mm3). By 4 wk, only 9 of 20 primary animals under- 
going hematopoietic reconstitution were still alive, and these 
animals were visibly ill (showing  substantial weight loss, 
ruffled fur, and a hunched posture). The animals with the 
most severe symptoms (7/9) were those that had received 
infected bone marrow that had been transiently cultured in 
the presence of G418 before injection. 
Serial  Transplantation of IL6-induced  Hematologic  Disease, 
Seven moribund mice were immediately killed for autopsy, 
and their bone marrow was transplanted to lethally irradi- 
ated secondary recipients (two to three secondaries per pri- 
mary) in an attempt to transfer the syndrome via infected 
stern cells. Mice 31 and 32, which had been transfused with 
infected bone marrow that had not been exposed to G418 
ex vivo, were killed 9 and 10 wk posttransplant, respectively, 
when their peripheral leukocyte counts were >300  x  103 
cells/mm  3.  All of the secondary recipients receiving bone 
marrow from the affected primary animals presented with 
leukocytosis 3-4 wk after transplant. Despite the elevated leu- 
kocyte levels, some of the secondary recipients survived for 
periods of up to 13 wk. These data suggested the possibility 
that functional integration of MSCV-I1:6 viruses had occurred 
at the level of repopulating stem cells. Consistent with this 
notion was the finding that the hematologic disease could 
be serially transferred to lethally irradiated tertiary (total of 
10)  and quaternary (total  of two)  recipients.  In  all  cases, 
Southern blot analysis with a neo probe revealed the pres- 
ence of nonrearranged MSCV-I1:6 proviruses in NheI-digested 
DNA from bone marrow or spleen (NheI cleaves once within 
each LTR yielding a fragment 3.9 kb in size; see Fig.  1). A1- 
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Figure 2.  Leukocytosis  and vari- 
able platdet levels in MSCV-Ib6 
mice. Peripheral  blood of  mouse  31 
(O), and its secondary  (I), tertiary 
(A), and quaternary  (￿9 recipients 
was analyzed  at the time points in- 
dicated after bone marrow trans- 
plantation. (A) Leukocyte  (WBC) 
counts were  routinely  >100 x  103 
cells/mm  3 compared with control 
values, which  were 2.9-16.0 x  103 
cells/mm  3 during an equivalent  ob- 
servation  period. (B) Platelet  counts 
varied widely (range, 62-5,008 x 
103  cells/mm3), with  mice fre- 
quently displaying  thrombocytosis 
or thromboeytopenia.  By compar- 
ison, platelet  counts  of  controls sta- 
bilized by 4 wk after transplanta- 
tion  (range, 884-1232  x  103 
cells/mm3). See Tables 1 and 2 for 
values of  hematologic  parameters  of 
31 series mice and controls before 
death. 
together, nine separate transplant pedigrees involving a total 
of 43 animals were established. The hematologic and patho- 
logic features of the syndrome were similar for all mice ex- 
amined. Most of the data presented were provided by two 
transplant pedigrees, one arising from infected bone marrow 
that had been selected in G418 (41 series) and one originating 
from infected bone marrow in which the selection had been 
omitted (31  series). 
Hematopathologic Changes Associated with Myeloproliferative 
Disease in MSCV-IL6 Mice.  Sustained leukocytosis was ob- 
served in the MSCV-IL-6 mice for a maximum of 15 wk after 
transplant (Fig.  2 A,  Table 1), with the mice either dying 
or killed for health concerns by this time (usually when one 
of the affected cohorts died). Differential cell counts performed 
on Wright-stained blood smears indicated that the increase 
in leukocytes was due primarily to excess numbers of mature 
neutrophilic granulocytes (Table 1, Fig. 3 D). With one ex- 
ception, all MSCV-IL-6 animals developing the myeloprolifer- 
ative syndrome also developed a microcytic anemia (mean he- 
matocrit of MSCV-Ib6 animals was 30% compared with 44% 
for concurrent controls receiving bone marrow infected with 
another MSCV construct or unirradiated littermates; Table 
2). The exception, mouse 31.3, presented with a macrocytic 
anemia (MCV of 74.8  fl compared with 37.5  fl for other 
MSCV-Ib6 mice and 42.4 fl for controls; Table 2).  Consis- 
tent  with  previously  reported  megakaryocytopoietic and 
thrombopoietic effects oflL6 (16, 18, 24), many MSCV-IL-6 
mice had higher than normal platelet levels throughout the 
observation period (Fig.  2 B).  However, other MSCV-Ib-6 
mice showed minor changes in platelet levels and a significant 
fraction of the mice eventually became thrombocytopenic 
(Table  2).  In most cases,  MPV was increased (Table  2),  a 
phenomenon typically seen in myeloproliferative disease (67). 
Suboptimal levels of synergistic factors required for e~cient 
stimulation of platelet production  (68)  would account for 
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the variable effects on platelet levels by II.-6. The variability 
in platelet numbers probably also reflects additional hemato- 
logic complications arising as a consequence of systemic IL-6 
action on organs such as the liver or kidney (see below). 
On autopsy (see Fig. 3 A), the most noticeable tissue change 
in the MSCV-IL-6 mice was an enlarged spleen (5-10-fold 
larger than normal) frequently containing white nodules. 
In view of the striking lymph node expansion (up to 1 cm in 
diameter) due to plasma cell infiltration seen previously in 
mice expressing exogenous Ib6 genes (39, 65), it was notable 
that in the vast majority of MSCV-Ib6 mice minimal lymph 
node swelling was observed. When moderate enlargement 
of the mesenteric lymph node occurred, it was mainly in seri- 
ally transplanted animals surviving 8 wk or longer. Autopsy 
also frequently revealed a small or undetectable thymus and 
pale diffuse areas of the liver. 
Upon histologic examination, the increased cellularity in 
the spleen was found to be due predominantly to expansion 
of the red pulp with an increased number of primitive my- 
eloid cells and neutrophils in various stages of differentiation 
(Fig. 3 B). Megakaryocytes were the other cell type frequently 
recognized (Fig.  3 C).  Inspection of multiple arbitrary mi- 
croscopic areas gave values as high as 40-50 megakaryocytes 
per  10 high-power fields,  compared with control spleens, 
which contained one to two megakaryocytes per 10 high- 
power fields. Comparably minor changes were observed in 
sternal marrow, similar to previous findings in mice having 
lower circulating Ib6 levels (39, 43), with an increased per- 
centage of neutrophils being the most prominent finding. 
Neutrophilic infiltrates were prevalent in the alveolar septae 
of the lung without evidence of bacterial infection (Fig.  3 
E), and in the periportal areas of the liver (Fig.  3 F). Some 
neutrophils were also present in hepatic sinusoids,  and focal 
neutrophilic infiltrates were found in an occasional expanded 
lymph node (Fig. 3 C) and, less commonly, in the interstitium Table  1.  Pe@heral Leukocyte  Counts and CFC Frequency in MSCV-IL-6 Mice 
Differential*  CFC  CFC 
Time of  in bone marrow*  in spleen# 
Mouse  reconstitution  IL-6  WBC  Ly  Gr  Mo  Eo  (%G418R)  (%G418R) 
wk  ng/ml  x 10  J cells/ram  3 
31  9  75  350  2  96  1  1  ND  ND 
31.1  13  22  370  4  94  2  0  6,800  (<1)  13,000  (<1) 
31.2  13  ND  250  2  97  1  0  ND  ND 
31.3  4  43  350  1  98  1  0  3,000  (<1)  7,600  (3) 
31.1.1  6  62  135  5  92  2  1  12,000  (<1)  12,800  (<1) 
31.1.2  6  42  160  4  92  4  0  12,300  (<1)  5,500  (<1) 
31.3.1  11  65  176  7  90  3  0  7,700  (1)  9,000  (<1) 
31.3.2  15  130  310  3  94  3  0  10,000  (2)  7,600  (1) 
31.3.1.1  4  58  250  2  95  3  0  7,700  (1)  10,300  (<1) 
31.3.1.2  4  54  190  4  95  1  0  9,000  (<1)  7,000  (1) 
41  4  65  49.2  2  98  0  0  35,000  (17)  6,500  (18) 
41.1  9  14  270  1  98  1  0  13,500  (30)  10,300  (26) 
41.2  9  45  120  4  96  0  0  10,000  (55)  8,000  (69) 
41.3  9  18  430  3  95  2  0  10,800  (74)  17,000  (73) 
41.3.1  7  48  125  3  96  1  0  10,700  (67)  6,000  (50) 
41.3.2  7  7  120  6  94  0  0  12,500  (56)  9,200  (49) 
51  8  ND  11.0  77  20  3  0  8,500  (<1)  90  (7) 
52  8  ND  5.6  73  27  ND  ND  ND  ND 
53  8  ND  7.6  83  17  ND  ND  ND  ND 
54  12  ND  12.1  84  16  ND  ND  7,700  (<1)  200  (<1) 
55  12  ND  13.1  84  16  ND  ND  ND  ND 
56  12  ND  8.5  82  18  ND  ND  ND  ND 
BALB/c  -  <0.1  11.9  _+  2.1  83  +  5  17  _+  6  1  +  1  1  +  1  5,300  +_  1,300  175  _+  120 
MSCV-IL-6-infected bone marrow from mouse 31 was serially transplanted to three secondary recipients (mice 31.1, 31.2, and 31.3), four tertiary 
recipients (mice 31.1.1, 31.1.2, 31.3.1, and 31.3.2), and two quaternary recipients (mice 31.3.1.1 and 31.3.1.2).  Mouse 31.2 died 14 wk after trans- 
plantation.  MSCV-IL-6-infected bone marrow  from mouse 41 was serially transplanted to three secondary recipients (mice 41.1, 41.2,  and 41.3) 
and two tertiary recipients (mice 41.3.1 and 41.3.2). Mice 51-56 are primary recipients of bone marrow infected with another MSCV construct. 
BALB/c values represent the mean and standard error of values obtained for six normal mice. WBC, leukocytes; Ly, lymphocytes; Gr, mature neu- 
trophils (m2% band forms); Mo, monocytes; Eo, eosinophils. 
* Manual differential leukocyte counts were performed on 200 cells. Automated  differential leukocyte counts are presented for mice 52-56. 
CFC frequency is expressed per 106 bone marrow  or spleen cells. Numbers in parentheses indicate the percentage of progenitor  cells that were 
G418 resistant. 
Figure 3.  Hematopathologic analysis  of MSCV-Ib6 mice with myeloproliferative  disease. (,4) Dissection of affected  secondary recipient demonstrating 
enlarged spleen with white nodules (lower arrow), swollen mesenteric lymph node (middle arrow), and small thymus (upper arrow). Also apparent are 
discolored splotchy areas of the liver. (B) Section of spleen showing considerable  expansion of red pulp with neutrophils and immature myeloid elements 
(x600).  (C) Section of spleen illustrating increased numbers of megakaryocytes (x 600). (D) Peripheral blood smear showing predominance of mature 
neutrophils (xl,000). (E) Section of lung showing extensive interstitial neutrophilic infiltration (x600).  (F) Section of liver showing periportal neu- 
trophilic infiltration as well as some neutrophils in hepatic sinusoids (x 250); abnormalities in hepatocytes are more clearly evident in the high-power 
image of Fig. 5. (G) Section of lymph node showing focal accumulations of neutrophils intermixed with diffuse infiltrate of plasma cells (x600).  (/4) 
Section of thymus showing normal-appearing  lymphocytes  in meduUa (top) and cortex (bottom) (x  600). (/')  Smear  of factor-independent,  bone marrow-derived 
colony showing macrophages and cells of granulocytic lineage at various stages of differentiation (xl,500). 
1154  Interleukin 6-induced  Myeloproliferative  Disease 1155  Hawley ct al. Table  2.  Other  Hematologic Changes Associated with IL-6-induced Myeloproliferative Disease 
Mouse  RBC  Hemoglobin  Hematocrit  MCV  Platelets  MPV 
x  10  ~ cells~ram  J  $/d  ~o  fl  x  103 cells~ram 3  fl 
31  8.76  13.2  33.2  37.8  1,248  9.0 
31.1  7.00  11.2  27.6  39.6  2,004  6.5 
31.2  6.24  10.0  25.6  41.0  1,724  6.9 
31.3  3.06  7.6  22.8  74.8  2,060  4.0 
31.1.1  8.68  11.2  30.0  34.5  1,708  9.2 
31.1.2  8.62  11.4  31.2  36.2  1,666  8.9 
31.3.1  8.44  12.0  32.0  37.7  552  10.4 
31.3.2  7.84  12.0  32.0  40.7  2,880  6.2 
31.3.1.1  8.70  13.6  35.0  40.2  2,214  6.4 
31.3.1.2  8.56  12.4  34.0  39.5  1,932  6.8 
41  7.84  11.2  31.2  39.7  1,464  8.0 
41.1  8.24  12.4  31.2  38.0  140  14.4 
41.2  8.40  10.8  29.6  35.2  1,180  10.4 
41.3  8.36  12.8  30.0  36.0  820  12.3 
41.3.1  9.10  11.8  31.8  34.9  938  10.7 
41.3.2  9.02  11.6  30.6  34.0  106  15.0 
51  9.79  15.1  41.5  42.4  1,168  5.4 
52  10.45  15.9  44.1  42.2  1,117  5.6 
53  10.42  15.3  44.8  43.0  1,048  5.4 
54  t0.37  16.3  43.5  41.9  1,109  6.4 
55  10.15  15.9  42.4  41.8  1,080  6.5 
56  10.01  16.4  43.1  43.1  1,061  6.4 
BALB/c  9.7"/ _+  0.79  15.4 +_  1.3  43.9  _+  3.6  44.9  +_  0.7  1,096  +  217  5.8  +  0.9 
MCV, mean corpuscular volume; MPV,  mean platelet volume; RBC,  erythrocytes. See Table 1 footnotes for details of nomenclature. 
of the kidney. Despite the presence of large numbers of cir- 
culating neutrophils, there was no histologic evidence of in- 
creased  neutrophil  accumulation in  the  skin  (D.  Sauder, 
personal communication). Compared with the massive neu- 
trophilia seen in these tissues, focal infiltrates of plasma cells 
were only rarely observed. In these instances,  plasma cells 
were found intermixed with neutrophil infiltrates in expanded 
lymph nodes (Fig. 3 G), with a few small loci of plasma cells 
infrequently observed in the spleen.  No evidence of plasma 
cell infiltration of lung, liver,  or thymus (Fig.  3 H) could 
be found. 
In parallel with the histologic findings in spleen and bone 
marrow, progenitor cell numbers were elevated 30-60-fold 
and "~2-fold, respectively, in these tissues (Table 1). The fre- 
quencies  of the various colony types were not determined, 
but granulocyte and/or macrophage colonies were prominent 
and proportionally fewer colonies contained erythroid ele- 
ments than those formed in respective control cultures of  spleen 
or bone marrow cells (data not shown). Interestingly, there 
was a difference in the percentage of G418-resistant  progen- 
itors found in the various mice, depending on whether or 
not the bone marrow had been subjected to G418 selection. 
Whereas 20-80%  of the progenitors in the bone marrow 
and spleen of mice receiving preselected bone marrow were 
G418 resistant, at most a few percent of the progenitors in 
the two mice receiving nonselected bone marrow grew in 
G418-supplemented medium (Table 1, discussed below). When 
plated in the absence of added factors,  "~10% of spleen and 
bone marrow  CFC were found to  be  factor independent 
regardless of frequency of G418 resistance. 10 individual factor- 
independent colonies arising from spleen  or bone marrow 
cells of two mice with G418-resistant progenitors were picked, 
smeared onto microscope slides, Wright-stained, and scored. 
In both cases, the colonies were comprised of macrophages 
or neutrophils and macrophages (Fig. 3/), irrespective of the 
tissue source. These results concur with previous reports of 
the ability of exogenously supplied IL-6 to directly support 
the proliferation of some murine granulocyte/macrophage  pro- 
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Cellulose acetate  electrophoresis  of plasma obtained from mice 31 (lane 
31) and 41 (lane  41) revealing  marked  alterations  in levels  of  albumin  (Alb) 
and protein(s) in the ot2-macroglobulin/haptoglobin  region (arrow)  by 
comparison  with the protein  pattern  of  normal  BALB/c  plasma (lane  Ba). 
(B) Densitometric  profiles  of  cellulose  acetate  electrophoresis  protein  pat- 
terns of  mouse  41 (solid  line) and normal  BALB/c  (dashed  line) demonstrating 
the diffusely  increased  Ig fraction  in mouse 41 plasma. 
genitors (14, 15, 20). Since m30% of the factor-independent 
CFC were G418 resistant in these instances (data not shown), 
autocrine as well as paracrine mechanisms of IL-6 stimula- 
tion contribute to the myeloproliferative syndrome. 
When pools of the G418-resistant  factor-independent colo- 
nies were transferred to mass culture, the cells proliferated 
for -4 wk, at which time they were comprised of adherent 
macrophages. In a separate experiment, infected spleen cells 
(2  x  106) were injected subcutaneously into  eight suble- 
thally irradiated (4 Gy) mice. No tumors formed during an 
observation period of 3 too, whereas six lethally irradiated 
mice receiving bone marrow transplants from the same affected 
donor died from the myeloproliferative disorder during this 
period (data not shown). 
Excessive  11,6 Production and Systemic Effects  in MSCVIL.6 
Mice.  Plasma obtained from MSCV-ID6 mice before death 
was analyzed for II,6 activity by testing the ability of serial 
dilutions to stimulate the proliferation of II..6-dependent B9 
cells (58). Circulating levels of II.-6 were significantly elevated 
in all mice (mean, 50 ng/ml; range, 7-130 ng/ml; n  =  15) 
compared  with  control  plasma,  which  had  minimal  B9 
stimulator)" activity (<0.1 ng/ml) (Table  1). Failure of the 
plasma samples to stimulate the proliferation of OTT1, FDC- 
P1, or 32D cells (60, 61) at any dilution tested demonstrated 
that the increased number of peripheral neutrophils seen in 
the mice was not due to high levels of circulating GM-CSF 
or II-3  (35,  36). 
Cellulose acetate electrophoresis of plasma samples revealed 
decreased albumin levels and elevated protein levels in the ol2- 
macroglobulin/haptoglobin region (Fig. 4), indicative of the 
well-recognized activity of II,6 as a major regulator of the 
hepatic acute phase response (69). An increase in haptoglobin 
levels has been confirmed by rocket immunoelectrophoresis, 
and the results will be reported elsewhere as part of a larger 
study of acute phase protein synthesis in MSCV-IL-6 mice 
(J.  Gauldie and R.  G.  Hawley, unpublished results).  Also 
illustrated by comparison of plasma samples  from mice 31 
and 41 is a rise in Ig levels between 4 and 9 wk after trans- 
plantation  (Fig.  4),  although  less  so  than  the  hypergam- 
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Figure  5.  Pathologic  changes  in 
liver  and kidney  of  diseased  MSCV- 
II-6 mice. (.4) Section of control 
liver (x 1,000). (B) Section  of liver 
of MSCV-I1.6 mouse  showing  ab- 
normal  hepatocytes. Note  the 
markedly  enlarged  nuclei  with mul- 
tiple nucleoli  (x 1,000). (C) Section 
of  control  kidney  (x 600). (D) Sec- 
tion of  kidney  of  MSCV-I1.6  mouse 
showing  atrophic tubules and 
significantly  expanded  glomemlus 
due to mesangial cell hyperplasia 
(  x 600). maglobulinemia seen in the lymphoproliferative syndromes 
elicited by IL-6 overexpression  in other studies (39,  65). 
In addition to the pathologic consequences of neutrophil 
infiltration, sustained overproduction of Ib6 had direct effects 
on liver and kidney. Coincident with the marked changes 
in plasma levels of hepatic proteins, hepatocytes displayed sub- 
stantial nuclear and cytoplasmic enlargement (Fig. 5 B), the 
cytoplasm appearing more basophilic than normal, and de- 
generative changes were also apparent. Mesangial cell prolifer- 
ation with accompanying glomerular enlargement was the 
most common abnormality in the kidney (Fig. 5 D), as pre- 
viously reported (39, 65).  Other changes in the kidney in- 
cluded the presence of eosinophilic material apparently oc- 
cluding some of the capillaries and proteinaceous material 
in dilated and atrophic tubules in some regions of the cortex. 
Clonal Origin of  lb6-induced Myeloproliferative  Disease.  Ret- 
rovirus marking studies of stem cells have shown that early 
after transplantation multiple clones contribute to the hema- 
topoietic system but that with time the progeny of a few 
clones come to predominate (30, 31, 33). In certain instances 
when the retrovirally  marked bone marrow has been trans- 
planted to secondary recipients,  the predominant done has 
been transferred  (29, 32, 34). Conversely, clonal fluctuation 
of stem cell pools has been seen at early times during recon- 
stitution, and new clones can become activated by the trans- 
plantation process (30, 31, 33, 34, 70). In view of the relative 
ease with which the myeloproliferative  syndrome could be 
serially passaged in lethally irradiated recipients, we were in- 
terested in examining the fate maps of the clones contributing 
to the hematopoietic systems of the 31 and 41 series mice. 
DNA  from  bone marrow  and  spleen  was  digested with 
BamHI, which cleaves the MSCV-Ib6 provirus once (Fig. 
1), and were subjected to Southern blot analysis with a neo 
probe (Fig.  6).  In the case of mouse 31, kiUed 9 wk after 
transplant, three bands of 5.4,  12, and 14 kb were detected 
in the DNA from both tissues. Remarkably, these same three 
proviraljunction fragments were detected in the DNA from 
spleen and bone marrow samples of aU 31 series mice exam- 
ined (Fig.  6).  The progeny of a single cell carrying three 
MSCV-Ib6 proviruses had therefore successfully repopulated 
the hematopoietic systems of at least  nine mice, including 
two secondary, four tertiary,  and two quaternary recipients 
(tissue samples of mouse 31.2, which died 14 wk after trans- 
plantation, were unavailable for analysis). A slightly different 
pattern was revealed after Southern blot analysis of genomic 
DNAs from the 41 series recipients.  BamHI-digested DNA 
from bone marrow and spleen from mouse 41 (killed 4 wk 
after  transplant)  displayed  an  extremely large  number of 
proviral flanking sites, indicated by the presence of some pre- 
dominant bands superimposed on a background smear (Fig. 
6).  These results indicated that 4  wk after  bone marrow 
transfer, the hematopoietic system of this animal was derived 
from  many  MSCV-Ib6-infected  cells. Upon  serial  bone 
marrow transfer,  a single done harboring one MSCV-IL6 
provirus was found to dominate. BamHI-digested DNA from 
spleen and bone marrow of three secondary recipients and 
two tertiary recipients  displayed a 5.0-kb proviral junction 
fragment (plus some additional bands in the case of the secon- 
Figure  6.  Clonal make-up of hematopoietic tissues of 31 and 41 series 
mice. Proviral integrants were enumerated in BamHI-digested  DNA from 
bone marrow (BM) and spleen (SP) of MSCV-Ib6 mice by Southern blot- 
ting with a neo probe.  (Top) A major clone identified  in bone marrow 
and spleen of mouse 31  (containing three proviral integrants) persisted 
in two secondary, four tertiary, and two quaternary affected recipients (the 
variability in signal intensities is due to unequal  sample loading in this 
experiment). (Bottom)  A minor clone (identified  by a 5.0-kb proviraljunc- 
tion fragment) in bone marrow of mouse 41 was found to have significant 
repopulating ability during serial bone marrow transplantation, transfer- 
ring the myeloproliferative  disease to three secondary and two tertiary 
recipients. 
daries), which was present as a minor band in mouse 41 bone 
marrow DNA (Fig. 6; other data not shown). Less detailed 
pedigree analysis carried out with 47 series mice revealed a 
similar phenomenon  whereby multiple clones in the primary 
animal gave rise to a small number (one or two) of dominant 
clones after  serial transplantation (data  not shown). 
High-Level Sustained Transcription of Viral 11_,6 Gene in Seri- 
ally Transplanted  MSCV-Ib6 Mice.  Northern blot analysis of 
total spleen RNA demonstrated persistent expression of viral 
Ib6 mRNA in all affected mice whose hematopoietic systems 
were reconstituted after serial transplantation of MSCV-Ib 
6-infected bone marrow (Fig. 7). There were, however, con- 
spicuous differences  in  expression  patterns of MSCV-IL-6 
proviruses in 31 and 41 series animals. In all 31 series animals, 
LTR-directed fuMength Ib6 mRNA plus a smaller Ib6 RNA 
species (4.0  and 3.6 kb, respectively)  were readily detected 
with the II.-6 probe (Fig. 7 A). The smaller 3.6-kb IL-6 RNA 
species (in addition to the 4.0-kb IL-6 mRNA) was detected 
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II.-6 proviruses in  serially trans- 
planted mice of 31 and 41 series. 
Total spleen  RNA was examined  by 
successive  Northern blot analysis  for 
the presence of Ib6  (top) or neo 
(middle) transcripts. The blots were 
rehybridized with a probe specific 
for glyceraldehyde-3-phosphate  de- 
hydrogenase (GAPDH)  mRNA to 
monitor the amount and integrity 
of RNA loaded (bottom). (A) The 
major viral RNA species  expressed 
in 31 series mice are Ib6 mRNAs 
(4.0 and 3.6 kb). (/3) The 4.0-kb 
full-length Ib6  mRNA  and  the 
1.6-kb pgbl-directed neo mRNA 
are the most abundant viral KNA 
species in 41 series mice. A similar 
viral KNA  expression pattern is 
observed  in primary  mouse  47. Ad- 
ditional RNAs detected with the 
IL-6 probe  originate from  the endog- 
enous Ib6 gene. 
by the neo probe upon rehybridization of the blot and corre- 
sponds to a spliced product frequently observed in retrovirus 
vectors which include the extended packaging region and re- 
tain a functional splice donor site (48).  Normally,  the full- 
length  II.-6 mKNA is present  at  significantly higher  levels 
than  the 3.6-kb species  in MSCV-IL-6-infected cells (Fig.  7 
B). More curious, however, was the virtual absence of pgk-1- 
initiated neo transcripts (a faint band at 1.6 kb corresponding 
in size to neo mKNA was visible upon longer exposure of 
the blot).  The relative paucity of pgk-l-initiated  neo tran- 
scripts  in  hematopoietic  tissues of 31  series  mice contrasts 
sharply with our previous findings in mice transplanted with 
bone marrow infected with the MoMLV-based L6PNL II.-6 
retrovirus, where the pgk-l-initiated neo transcripts were by 
far the most abundant RNA species (43). Emerman and Temin 
(71) have documented the phenomenon  of "promoter  sup- 
pression" in retrovirus vectors having  an internal  transcrip- 
tional unit. Their studies showed that in these "direct orien- 
tation" retrovirus vectors (72) suppression of either the LTK 
promoter or the downstream promoter can occur when there 
is selection for expression from the other promoter.  In our 
previous studies (and in the majority of the current experi- 
ments), neo gene expression was selected for by culturing in- 
fected bone marrow cells in G418 before transplantation.  The 
possibility that Ib6 gene expression might have been selected 
for in repopulating  cells  of 31  series  mice is an  intriguing 
notion warranting further study. In any event, the extremely 
low levels  of neo transcripts  originating  from  MSCV-IL-6 
proviruses present in the spleen cells of 31 series animals ex- 
plain  the  scarcity of G418-resistant  progenitor  cells in  the 
CFC  assays. 
In contradistinction  to L6PNL mice and 31  series  mice, 
both full-length LTR-directed Ib6 mRNA and pgk-l-directed 
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neo transcripts  (4.0 and  1.6  kb, respectively) were present 
at high levels in splenic KNAs of 41 series mice serially trans- 
planted with G418-selected bone marrow (Fig.  6 B). Exclu- 
sive of the higher overall levels of MSCV-IIr  viral transcripts 
seen in primary recipient mouse 41 (and mouse 47), the level 
of MSCV-IL-6 gene expression remained stable after multiple 
transplants. 
Discussion 
The main finding of this paper is that the sustained in vivo 
expression of a retrovirally introduced Ib6 gene in hemato- 
poietic precursors results in a novel serially transplantable my- 
eloproliferative disease. 
Several of the characteristic  features of the IL-6-induced my- 
eloproliferative  disease  (neutrophilia,  anemia,  and  hypoal- 
buminemia) were also seen previously in unirradiated W/W v 
mice transplanted  with  bone marrow cells  infected with  a 
MoMLV-based IL-6 retrovirus  (39).  A  major difference be- 
tween our results and those of Brandt et al. (39) is the severity 
of the disease that develops. In the current experiments, many 
primary recipients (11/20) died within 4 wk of transplant, 
whereas only two animals  died during  the same period in 
their  study.  Although  a direct comparison of IL-6 levels is 
precluded by differences in  the units  of measurement  used 
to report Ib6 activity, the increased morbidity seen in our 
experiments is probably due to higher concentrations of cir- 
culating IL-6 promoted by the MSCV retrovirus configura- 
tion  (see  below).  Indirect  support  for  this  suggestion  is 
provided by the more striking changes in plasma protein levels 
seen  in  the  MSCV-IL-6  mice. 
In the syndrome that developed in the II.-6 mice of Brandt 
et al. (39), the neutrophilia was transient and superseded by excessive production of plasma cells. Plasmacytosis was also 
the salient feature of a syndrome observed by Suematsu et 
al. (65) in I1:6 transgenic mice. In the latter case, it can be 
estimated that the plasma levels of I1:6 are 10-fold lower on 
average than those found in the MSCV-I1:6 mice. However, 
higher I1:6 levels alone would not appear to explain the bias 
towards persistent myeloid expansion seen in our studies. It 
seems more likely that the different  transcriptional regula- 
tory elements directing I1:6 expression are to a large degree 
responsible for the differences in disease phenotypes. The com- 
bination of variant LTR (a derivative of the myeloprolifera- 
rive sarcoma virus LTR) and the 5' untranslated region of 
the MESV vector permits transcription in a range of cell types, 
including embryonal (44) and myeloid (73) cells. By com- 
parison, the MoMLV LTR used in the bone marrow trans- 
plant experiments of Brandt et al. (39) and the Ig heavy chain 
enhancer used in the transgenic experiments of Suematsu et 
al.  (65) are preferentially  active in lymphoid cells (74-77). 
Earlier studies showing that substitution of the myeloprolifer- 
ative  sarcoma  virus LTR with the MoMLV LTR greatly 
reduces the myeloid-transforming ability of the v-mos oncogene 
(78,  79) lend credence  to this idea. 
In contrast to the fatal myeloproliferative diseases that de- 
velop in mice transplanted with GM-CSF and I1:3 virus- 
infected bone marrow cells (35, 36), where extensive tissue 
damage results from the surplus of hematopoietic cells pro- 
duced (mainly neutrophils and macrophages), minimal ex- 
travasation of neutrophils from the blood occurs in MSCV- 
I1:6 mice. This situation is similar to that observed in mice 
whose hematopoietic cells have been engineered to overex- 
press G-CSF, where little sign of tissue damage was observed 
despite  sustained  elevation  of  neutrophil  numbers  (38). 
Nevertheless, whereas the mice overexpressing G-CSF remain 
healthy for periods of up to 30 wk after transplantation, the 
majority of MSCV-I1:6 mice fail to survive >12 wk. Pre- 
sumably, additional clinical manifestations (anemia, throm- 
bocytopenia, and coagulation abnormalities) associated with 
the I1:6-induced "hematological stress syndrome" (69), plus 
complications due to multisystem damage (especially liver 
and kidney), all contribute to the early demise of the animals. 
Interestingly, many of the clinical features of the syndrome 
that develops in the MSCV-I1:6 mice are reminiscent of those 
observed in patients with alcoholic hepatitis, a distinct clin- 
ical entity that resembles severe sepsis and fulminant hepatic 
failure (80). Patients with advanced disease have neutrophilia, 
severe coagulopathy, activation of acute phase proteins, and 
acute renal failure,  and frequently die of hepatic failure or 
gastrointestinal hemorrhage. High plasma levels of I1:6 have 
been found to correlate  with disease severity and mortality 
(80). Our data support the hypothesis that chronically elevated 
Ib6 levels play a contributory role in this human disorder. 
Considering the fact that transplantation has deleterious 
effects on the repopulating ability of normal stem cells (29, 
81, 82) and that I1:6 exhibits differentiation-inducing  activity 
on granulocyte/macrophage  progenitors (15; this report), the 
proliferative capacity of MSCV-Ib6-infected cells is impres- 
sive. It seems reasonable therefore to suggest that Ib6 played 
a supportive role in the maintenance of clonal longevity. When 
the experiments were terminated, the longest observed clone 
of the  31  series  had endured for  at  least  1.5  yr  in  nine 
(documented) recipients.  Although uninfected hematopoi- 
etic cells (of donor or host origin) undoubtedly contributed 
to the myeloproliferative disease, their presence does not in- 
validate this result; self-renewal of the repopulating precursors 
occurred for the equivalent of (most of) a mouse's lifetime. 
The MSCV-Ib6-infected repopulating cells can thus be re- 
garded as stem cells (83). Whether the cells in question are 
the most primitive stem cells (i.e., capable of long-term mul- 
tilineage reconstitution [84, 85]) remains to be clarified. In 
limited Southern blotting experiments of other MSCV-I1:6 
mice, the same unique proviral integration sites identified in 
DNA from bone marrow and peripheral tissues were detected 
in DNA from lymph nodes and thymus. However, lymphoid 
potential of the clones could not be concluded  because infiltra- 
tion by neutrophils in the lymph nodes or contamination 
of the thymus by adjacent infiltrated thoracic lymph nodes 
could not be ruled out (our unpublished results).  The issue 
of differentiative potential of MSCV-Ib6-infected precursors 
can be addressed by isolating purified populations of lym- 
phoid and myeloid cells (43).  To investigate this and other 
biologic properties of these hematopoietic precursors, it would 
be advantageous to be able to prolong the lifetimes of MSCV- 
I1:6 mice by reducing the toxic effects associated with high 
circulating levels of Ib6. Toward this goal, a modified Ib6 
retrovirus vector has been constructed carrying an II..6 gene 
with a synthetic sequence added to its COOH  terminus 
(KDEL sequence) that is present on proteins retained within 
the endoplasmic reticulum (86). 
In the avian system, autocrine production of chicken my- 
elomonocytic growth factor, a cytokine distantly related to 
mammalian I1:6, is a key step in myeloid  lenkemogenesis (87). 
As the role of Ib6 in human myeloid leukemia remains un- 
clear (88-90), the Ib6-induced myeloproliferative model de- 
veloped here may prove a useful mammalian system for in- 
vestigations along these lines. Indeed, II:6 transgenic mice 
have already provided evidence that dysregulated II.-6 expres- 
sion can contribute to the development of lymphoid neo- 
plasms (91). 
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